Denise M. Wolf

University of California, San Francisco (UCSF)

Third Avenue and Parnassus

San Francisco, CA 94143

United States

SCHOLARLY PAPERS

1

DOWNLOADS

6

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (1)

1.

Durvalumab With Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results From the Adaptively Randomized I-SPY2 Platform Trial

Number of pages: 41 Posted: 19 Dec 2020
Yale University, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), Moffitt Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of California, San Diego (UCSD), University of Alabama at Birmingham, Mayo Clinic, University of California, San Francisco (UCSF), University of Colorado, The University of Minnesota, University of Chicago, Loyola University of Chicago - Stritch School of Medicine, University of Pennsylvania, Oregon Health and Science University, Columbia University, Georgetown University, Wake Forest University, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of Alabama at Birmingham, Mayo Clinic, University of California, San Francisco (UCSF), George Mason University, George Mason University, Quantum Leap Healthcare Collaborative, Quantum Leap Healthcare Collaborative, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), Berry Consultants, LLC, Berry Consultants, LLC, Quantum Leap Healthcare Collaborative, University of California, San Francisco (UCSF), Gemini Group, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Diego (UCSD), University of Texas at Houston - MD Anderson Cancer Center, The University of Minnesota, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of Pennsylvania, Berry Consultants, LLC and University of California, San Francisco (UCSF)
Downloads 6 (715,501)

Abstract:

Loading...

Breast cancer; immunotherapy; DNA repair inhibitor; clinical trial